Edge advances in nanodrug therapies for osteoarthritis treatment DOI Creative Commons
Jinfeng Liao, Qinxuan Gu,

Zheng Liu

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 30, 2024

As global population and lifestyles change, osteoarthritis (OA) is becoming a major healthcare challenge world. OA, chronic condition characterized by inflammatory degeneration, often present with joint pain can lead to irreversible disability. While there currently no cure for it commonly managed using nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, glucosamine. Although these treatments alleviate symptoms, difficult effectively deliver sustain therapeutic agents within joints. The emergence of nanotechnology, particularly in form smart nanomedicine, has introduced innovative approaches OA treatment. Nanotherapeutic strategies offer promising advantages, including more precise targeting affected areas, prolonged effects, enhanced bioavailability, reduced systemic toxicity compared traditional treatments. nanoparticles show potential as viable delivery system therapies based on encouraging lab-based clinical trials results, remails considerable gap between current research application. This review highlights recent advances nanotherapy explore future pathways refine optimize strategies.

Language: Английский

Folate-engineered chitosan nanoparticles: next-generation anticancer nanocarriers DOI Creative Commons
Prashant Kesharwani,

Kratika Halwai,

Saurav Kumar Jha

et al.

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: Oct. 31, 2024

Chitosan nanoparticles (NPs) are well-recognized as promising vehicles for delivering anticancer drugs due to their distinctive characteristics. They have the potential enclose hydrophobic molecules, thereby enhancing solubilities, permeabilities, and bioavailabilities; without use of surfactant, i.e., through surfactant-free solubilization. This allows higher drug concentrations at tumor sites, prevents excessive toxicity imparted by surfactants, could circumvent resistance. Moreover, biomedical engineers formulation scientists can also fabricate chitosan NPs slowly release agents. keeps site longer, makes therapy more effective, lowers frequency dosing. Notably, some types cancer cells (fallopian tube, epithelial tumors ovary, primary peritoneum; lung, kidney, ependymal brain, uterus, breast, colon, malignant pleural mesothelioma) overexpression folate receptors (FRs) on outer surface, which lets folate-drug conjugate–incorporated target kill them effectively. Strikingly, there is evidence suggesting that excessively produced FR&αgr (isoforms FR) stays consistent throughout treatment in ovarian endometrial cancer, indicating resistance conventional treatment; this regard, folate-anchored overcome it improve therapeutic outcomes. Interestingly, overly expressed FRs present only certain types, a biomarker predicting effectiveness FR-targeted therapy. On other hand, folate-modified enhance oral absorption medicines, especially drugs, pave way effective long-term low-dose metronomic scheduling poorly soluble permeable drugs. In review, we talked briefly about techniques used create, characterize, tailor chitosan-based NPs; delved deeper into applications folate-engineered treating various types. Schematic illustration ligand-drug incorporated its advantage cancer. Figure created with BioRender.Com.

Language: Английский

Citations

8
Harnessing phytoconstituents in ethosomes: A new frontier in skin disorder management DOI
Monika Chauhan,

Jyoti Chandra,

Garima Gupta

et al.

International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125273 - 125273

Published: Jan. 1, 2025

Language: Английский

Citations

1
Current Status of Gout Arthritis: Current Approaches to Gout Arthritis Treatment: Nanoparticles Delivery Systems Approach DOI Creative Commons
Yedi Herdiana, Yoga Windhu Wardhana, Insan Sunan Kurniawansyah

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(1), P. 102 - 102

Published: Jan. 14, 2025

The deposition of monosodium urate (MSU) crystals within joint spaces produces a painful inflammatory condition known as gout, specific form arthritis. calls for combined curative and preventive management model. A new development in the approach to gout is that NLRP3-targeted biologic agents, such monoclonal therapies, provide more accurate treatment by blocking pro-inflammatory cytokines. Nanoparticle drug delivery enhances biological availability targets, which may increase therapeutic efficacy decrease general toxicity. again cannot be ignored, mainly keeping up certain modifications diet weight, along with pharmacological therapies reduce uric acid (UA) levels frequency acute attacks. advancement genetic profiling patients biomarker discoveries drives trend towards building individualized medicine care, quickly gaining ground most effective method delivering treatments individual patients, moving away from one-size-fits-all treatments. following paper aims an updated account focus on recent developments, order enhance these approaches, quality life standard treatment.

Language: Английский

Citations

0
Eucalyptol Attenuates Indomethacin-Induced Gastric Ulcers in Rats by Modulating the ICAM-1, eNOS and COX/LOX Pathways: Insights from In Silico, In Vitro and In Vivo Approaches DOI Creative Commons

Urooj Iqbal,

Abdul Malik,

Nabeela Tabassum Sial

et al.

Food and Chemical Toxicology, Journal Year: 2025, Volume and Issue: unknown, P. 115319 - 115319

Published: Feb. 1, 2025

Language: Английский

Citations

0
Nano-Phytoconstituents: Recent Advances, Regulatory Insights, Challenges, and Future Horizons DOI
M H Miran Beygi, Fatemeh Oroojalian, Sercan Karav

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 106908 - 106908

Published: April 1, 2025

Language: Английский

Citations

0
Unlocking the future of osteoarthritis: Material engineering and drug delivery confluence for advanced therapeutic approaches DOI Creative Commons
Bhupendra Kumar, Laxmi Akhileshwar Jha, Prashant Pandey

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: 101, P. 106264 - 106264

Published: Oct. 9, 2024

Language: Английский

Citations

1
Edge advances in nanodrug therapies for osteoarthritis treatment DOI Creative Commons
Jinfeng Liao, Qinxuan Gu,

Zheng Liu

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 30, 2024

As global population and lifestyles change, osteoarthritis (OA) is becoming a major healthcare challenge world. OA, chronic condition characterized by inflammatory degeneration, often present with joint pain can lead to irreversible disability. While there currently no cure for it commonly managed using nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, glucosamine. Although these treatments alleviate symptoms, difficult effectively deliver sustain therapeutic agents within joints. The emergence of nanotechnology, particularly in form smart nanomedicine, has introduced innovative approaches OA treatment. Nanotherapeutic strategies offer promising advantages, including more precise targeting affected areas, prolonged effects, enhanced bioavailability, reduced systemic toxicity compared traditional treatments. nanoparticles show potential as viable delivery system therapies based on encouraging lab-based clinical trials results, remails considerable gap between current research application. This review highlights recent advances nanotherapy explore future pathways refine optimize strategies.

Language: Английский

Citations

1